WO2020085826A1

WO2020085826A1 - Composition for alleviation of skin irritation induced by environmental pollution factors or for skin protection, containing nutmeg extract or macelignan as active ingredient

Info

Publication number: WO2020085826A1
Application number: PCT/KR2019/014101
Authority: WO
Inventors: 황재관; 박지혜; 강하늘; 김창희; 정희철; 김도언
Original assignee: 연세대학교 산학협력단; (주)뉴트리
Priority date: 2018-10-26
Filing date: 2019-10-24
Publication date: 2020-04-30
Also published as: KR20200047422A; JP2022505979A; CN113613666A

Abstract

The present invention relates to a composition for the alleviation of skin irritation induced by environmental pollution factors or for skin protection, containing a nutmeg extract or macelignan as an active ingredient. A nutmeg extract and macelignan of the present invention have reduced the expression of gene CYP1A1 mediated by XRE, and have alleviated skin damaged by fine dust, thereby having excellent effects in the alleviation of skin irritation induced by environmental pollution factors and in skin protection. In addition, the composition of the present invention is a natural material, and thus can be safely used without side effects, thereby being usable as food and a cosmetic composition.

Description

Composition for alleviating skin irritation and protecting skin derived from environmental pollutants containing nutmeg extract or mace lignan as an active ingredient

This application claims priority to Korean Patent Application No. 10-2018-0129382 filed on October 26, 2018, and the entire specification is a reference of the present application.

The present invention relates to a composition for alleviating skin irritation and protecting skin derived from environmental pollutants containing nutmeg extract or mace lignan as an active ingredient, and more specifically, mace lignan represented by Formula 1 of the present invention or nutmeg containing the same It relates to a composition for skin irritation relief and skin protection derived from environmental pollution factors containing the extract as an active ingredient.

The skin protects the organs in the body from stimulation of the external environment and plays an important role in maintaining bio homeostasis such as body temperature control. However, exposure to excessive ultraviolet rays or pollutants causes skin irritation and eventually leads to skin aging. Among these external stimuli, fine dust and yellow sand mixed with harmful substances such as heavy metals are known to be major causes of skin aging and skin damage (J. Prev. Med. Public Health, 39: 205-212, 2006 ).

Particulate matter (PM) 10 is collectively referred to a particle size of 10 μm or less fine dust and fine particles less than 2.5 μm in seconds is divided into a PM _2.5. Fine dust is mainly generated when burning fossil fuels, and fine dust from China, which has a 70% dependency on coal, accounts for a large portion. On the other hand, yellow sand is a phenomenon in which small sand or loess is floating in the inland deserts of China and Mongolia, and is transported away by upper winds and falls near the ground. About 25 to 33% of diseases in industrialized countries are caused by environmental hazards. In Europe, it is estimated that approximately 310,000 people die prematurely each year from polluted air, and if the ultrafine dust increases by 10 μg per m ³ , the overall mortality rate increases by 7%. PM ₁₀ is regulated as an air pollutant in Korea, and air pollutants such as fine dust are known to cause respiratory and heart diseases (J. Exp. Biol. Med., 232: 1109-1118, 2007; J. Biosci., 28: 77-81, 2003).

In the case of sensitive skin, studies have shown that skin irritation occurs three times more than normal skin against environmental changes such as air pollutants. Particularly, PM _2.5 has smaller particles than ordinary dust, deep into the skin pores, causing skin trouble, and exacerbates various symptoms such as irritating dermatitis, acne, and allergic dermatitis. In addition, epidemiological studies show that skin exposed to fine dust increases wrinkles and directly affects aging. Polycyclic aromatic hydrocarbon (PAH) adsorbed on the surface of fine dust increases the activity of the aryl hydrocarbon receptor (AhR) and attaches to the xenobiotic response receptor (XRE), a cytochrome P450 (CYP) 1A1 gene mediated by XRE. Skin aging occurs as expression increases. Therefore, it is necessary to develop a safe and highly effective natural material capable of alleviating the skin irritation reaction caused by fine dust and yellow dust.

Accordingly, a material capable of preventing skin aging induced by environmental pollution factors is defined as an "antipollutant", and research has been conducted (Tsai MJ et al., J Mol Med (Berl)) 2014 Jun; 92 (6): 615-28 .; Ono Y et al., Exp Dermatol. 2013 May; 22 (5): 349-53), so far, there has been no significant research achievement.

Myristica fragrans belongs to the Myristicaceae family, and the seeds of Myristica fragrans are called nutmeg. So far, activities related to nutmeg have been reported such as detoxification, anti-diabetes, and anti-inflammatory effects. In addition, the representative ingredient contained in the nutmeg extract, macelignan, is a PPARα / γ dual agonist, and has been reported to have anti-diabetes, liver protection, neuroprotection, antibacterial, and antioxidant activities.

However, prior to the present invention, there is no known skin irritation mitigation and skin protection effect derived from environmental contaminants containing nutmeg extract or mace lignan as an active ingredient.

Accordingly, the present inventors searched for substances having a skin irritation relief and skin protection function derived from environmental pollutants derived from natural products, and found that nutmeg extract or mace lignan has a skin irritation relief and skin protection function derived from environmental pollution factors. The present invention was completed by clarification.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollutants containing nutmeg extract or mayslignan as an active ingredient.

In addition, an object of the present invention is to provide a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting of nutmeg extract or mays lignan as an active ingredient.

In addition, an object of the present invention is to provide a pharmaceutical composition for alleviating skin irritation and skin protection derived from environmental pollution factors consisting essentially of nutmeg extract or mays lignan as an active ingredient.

Another object of the present invention is to provide a food composition for alleviating skin irritation and skin protection derived from environmental contaminants containing nutmeg extract or mace lignan as an active ingredient.

In addition, another object of the present invention is to provide a food composition for skin irritation relief and skin protection derived from environmental pollutants consisting of nutmeg extract or macy lignan as an active ingredient.

In addition, another object of the present invention is to provide a food composition for alleviating skin irritation and skin protection derived from environmental pollution factors consisting essentially of nutmeg extract or mays lignan as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for skin irritation relief and skin protection derived from environmental pollutants containing nutmeg extract or macy lignan as an active ingredient.

In addition, another object of the present invention is to provide a cosmetic composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting of nutmeg extract or mays lignan as an active ingredient.

In addition, another object of the present invention is to provide a cosmetic composition for skin irritation relief and skin protection derived from environmental pollutants consisting essentially of nutmeg extract or mace lignan as an active ingredient.

Another object of the present invention is to provide a composition for preventing skin contamination derived from environmental contaminants containing nutmeg extract or mace lignan as an active ingredient.

In addition, another object of the present invention is to provide a composition for preventing skin contamination derived from environmental pollution factors consisting of nutmeg extract or mays lignan as an active ingredient.

In addition, another object of the present invention is to provide a composition for preventing skin contamination derived from environmental pollutants consisting essentially of nutmeg extract or mace lignan as an active ingredient.

Another object of the present invention is to provide a use of mace lignan or a nutmeg extract containing the same for preparing a preparation for skin irritation relief and skin protection derived from environmental pollution factors.

Another object of the present invention is a method for alleviating skin irritation and protecting skin induced from environmental pollutants, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. Is to provide.

Another object of the present invention is to provide a use of mace lignan or nutmeg extract containing the same for preparing a formulation for preventing skin contamination derived from environmental pollution factors.

Another object of the present invention is to provide a method for preventing skin contamination derived from environmental pollution factors, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. .

As a means for solving the above problems, the present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mays lignan as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollutants consisting of nutmeg extract or mace lignan as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollutants consisting essentially of nutmeg extract or macylignan as an active ingredient.

In order to achieve another object of the present invention, the present invention provides a food composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mace lignan.

In addition, the present invention provides a food composition for skin irritation relief and skin protection derived from environmental pollutants consisting of nutmeg extract or mace lignan.

In addition, the present invention provides a food composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting essentially of nutmeg extract or mace lignan.

In order to achieve another object of the present invention, the present invention provides a cosmetic composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mace lignan.

In addition, the present invention provides a cosmetic composition for skin irritation relief and skin protection derived from environmental pollutants consisting of nutmeg extract or mace lignan.

In addition, the present invention provides a cosmetic composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting essentially of nutmeg extract or mace lignan.

In order to achieve another object of the present invention, the present invention provides a composition for preventing skin contamination derived from environmental pollution factors containing nutmeg extract or mace lignan as an active ingredient.

In addition, the present invention provides a composition for preventing skin contamination derived from environmental pollutants consisting of nutmeg extract or mace lignan as an active ingredient.

In addition, the present invention provides a composition for preventing skin contamination derived from environmental pollutants consisting essentially of nutmeg extract or mace lignan as an active ingredient.

In order to achieve another object of the present invention, the present invention provides the use of mace lignan or a nutmeg extract containing the same to prepare a formulation for skin irritation relief and skin protection derived from environmental pollution factors.

In order to achieve another object of the present invention, the present invention derives from an environmental contaminant characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. Provides a method for alleviating irritation and protecting skin.

In order to achieve another object of the present invention, the present invention provides the use of mace lignan or nutmeg extract containing the same for preparing a formulation for preventing skin contamination derived from environmental pollution factors.

In order to achieve another object of the present invention, the present invention derives from an environmental contaminant characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. Provide a method for preventing contamination.

Hereinafter, the configuration of the present invention will be described in detail.

The present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mace lignan as an active ingredient.

The nutmeg extract is a Myristica plant of the Myristicaceae , and the seed of the myristica fragrant may be an extract target.

Specifically, the nutmeg extract may be extracted using water, an organic solvent having 1 to 6 carbon atoms, or a mixture thereof as a solvent. At this time, the organic solvent is C1 to C6 lower alcohol (alcohol), acetone (acetone), ether (ether), benzene (benzene), chloroform (chloroform), ethyl acetate (ethyl acetate), methylene chloride (methylene chloride), One or more selected from the group consisting of hexane, cyclohexane and petroleum ether is preferred, but is not limited thereto.

In addition, the lower alcohol used in the extraction of the nutmeg is also more preferably ethanol or methanol, most preferably ethanol.

After pulverizing the dried nutmeg at the time of extraction, it is preferable to extract water, alcohol or a mixture thereof by adding 2 to 20 times the weight of the crushed nutmeg, and it is more preferable to extract by adding 3 to 10 times. , But is not limited to this. The extraction temperature is preferably 20 ° C to 100 ° C, and more preferably 60 ° C to 100 ° C, but is not limited thereto.

The extraction time is preferably 1 hour to 10 hours, more preferably 2 hours to 5 hours, but is not limited thereto.

Cold extraction, ultrasonic extraction, or reflux cooling extraction may be used as the extraction method, and it is preferable to use a reflux cooling extraction method, but is not limited thereto. The number of extractions is preferably 1 to 5 times, and it is more preferable to repeatedly extract 2 to 3 times, but is not limited thereto.

In addition, the nutmeg extract may be performed by an ultra-high pressure, subcritical fluid or supercritical fluid extraction method.

Nutmeg used for extraction can be used after washing after harvesting or dried. As a drying method, a dry method, a dry method, a hot air drying method, and a natural drying method may be used. In addition, in order to increase the extraction efficiency, nutmeg or its dry matter may be crushed and used.

The macelignan preferably has the structure of Formula 1 below.

[Formula 1]

Macelignan (macelignan) of the present invention has a structure of formula 1, can be purified from nature, commercially available for use, or prepared by chemical synthesis methods known in the art.

Preferably, the machlignan of the present invention may be purified from nature. More preferably, it can be isolated and purified from Myristica fragrans , and most preferably, it can be isolated and purified from nutmeg or aril of Myristica fragrans . Another nutmeg, Myristica Myristica argentea Warb) (Nat. Prod. Lett., 16: 1-7, 2002), and Machilus thunbergii ) (Bio. Pharm. Bull., 27: 1305-1307, 2004), Leucas aspera , etc. (Chem. Pharm. Bull., 51: 595-598, 2003) .

Preferably, the may lignan of the present invention may be separated and purified from a nutmeg by a solvent extraction method known in the art and a separation method using chromatography.

According to one embodiment of the present invention, the composition according to the present invention can be used for alleviating skin irritation and protecting skin and preventing skin contamination derived from environmental pollutants by reducing the expression level of a gene mediated by XRE.

The composition of the present invention has a skin irritation alleviation and skin protection effect, and such skin irritation is a skin disease caused by deterioration of skin function due to environmental pollution factors, promotion of skin aging, etc., and is preferably a disease reported in the art. And protection.

Skin irritation of the present invention is more preferably any one or more selected from the group consisting of dermatitis, atopy, psoriasis, acne, skin cancer, eczema, It is not limited to this.

In addition, the skin irritation relief of the present invention may be "anti-pollution of the skin". Prevention of skin contamination improves skin condition by protecting the skin from natural factors (endogenous aging) or environmental pollutants (poly aromatic hydrocarbons, particulate matter, tobacco smoke, yellow sand or heavy metals, etc.) It means to induce, preferably to protect the skin from environmental pollution factors.

In the present invention, the term “mayslignan represented by Formula 1 or nutmeg extract containing the same” is considered to include their pharmaceutically acceptable salts or prodrugs thereof.

The term 'prodrug' in the present invention is a biotransformation in order to secrete or convert a prodrug into an active drug (eg, enzymatically, physiologically, mechanically, electromagnetically) in a targeted physiological system. Refers to a pharmaceutically inert derivative of the source 'drug' molecule (eg, primary or enzymatic) required. Prodrugs are designed to overcome problems associated with stability, toxicity, lack of specificity or limited bioavailability. Typical prodrugs include the active drug molecule itself and a chemical blocking group (e.g., a group that reversely inhibits the drug's activity). Some preferred drugs are variants or derivatives of components with separable groups depending on metabolic conditions. Typical drugs are pharmacologically activated both in vitro and in vitro when solvolysis under physiological conditions, enzymatic degradation, or other biochemical modifications (e.g. phosphorylation, hydrogenation, dehydrogenation, glycosylation reactions) are performed. . Prodrugs often offer advantages such as solubility, histocompatibility, or sustained release in the mammalian body. Common prodrugs include acid derivatives such as esters obtained by reacting a suitable alcohol (e.g., lower alkanols) with source acids, acylated base derivatives formed by reaction of amides or basic groups with amines and source acid components ( For example, lower alkylamide).

The nutmeg extract or mayslignan of the present invention may be included in the composition in the form of a pharmaceutically acceptable salt. “Pharmaceutically acceptable salt” refers to a physiologically acceptable salt that does not cause a common allergic reaction or similar reaction when administered to humans, and the salt is formed by a pharmaceutically acceptable free acid. Acid addition salts are preferred. As the free acid, an organic acid and an inorganic acid can be used. The organic acid is not limited thereto, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, Glutanoic acid and aspartic acid. In addition, the inorganic acids include, but are not limited to, hydrochloric acid, bromic acid, sulfuric acid and phosphoric acid.

The pharmaceutical composition of the present invention may be variously formulated according to the route of administration by a method known in the art together with a pharmaceutically acceptable carrier.

When formulated in the form of general pharmaceuticals, it is usually prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the mace lignan, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. It is prepared by mixing. In addition, lubricants such as magnesium styrene talc are used in addition to simple excipients. Liquid preparations for oral administration include suspensions, intravenous solutions, emulsions, syrups, etc.

In addition to the simple diluents commonly used, water and liquid paraffin, various excipients may be included, such as wetting agents, sweeteners, fragrances, and preservatives. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, ointments and creams. As non-aqueous solvents and suspension solvents, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used.

In addition, the composition of the present invention can be administered parenterally, parenteral administration is by subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method and transdermal administration method. To formulate a formulation for parenteral administration in an injection-injected manner, mayslignan is mixed in water with a stabilizer or a buffer to prepare a solution or suspension, which is formulated into unit dosage forms of ampoules or vials. The dosage unit can contain, for example, 1, 2, 3 or 4 times the individual dosage, or 1/2, 1/3 or 1/4 times. The individual dosage preferably contains the amount of effective drug administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage. In the case of transdermal dosage forms, ointments, creams, lotions, gels, external solutions, pasta agents, linen agents, aerosols, and the like are included. In the above, "dermal administration" means that the pharmaceutical composition is topically administered to the skin to deliver an effective amount of the active ingredient contained in the pharmaceutical composition into the skin.

The term 'pharmaceutically effective amount' in the present invention means an amount sufficient to alleviate skin irritation or protect the skin at a reasonable benefit / risk ratio applicable to medical uses, and the effective dose level is the individual type and severity, age, It can be determined by gender, drug activity, sensitivity to the drug, time of administration, route of administration and rate of excretion, duration of treatment, factors including co-drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be administered single or multiple. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect in a minimal amount without side effects, and can be easily determined by those skilled in the art.

These formulations are described in recipes generally known in pharmaceutical chemistry.

As other pharmaceutically acceptable carriers, reference may be made to those known in the art.

Furthermore, the pharmaceutical composition of the present invention may be administered in parallel with a known compound having an effect of preventing and treating skin irritation such as asthma and atopic dermatitis.

In another aspect, there is provided a method of alleviating or inhibiting skin irritation by administering the composition of the present invention to cells, tissues, organs, or individuals exhibiting skin irritation by heavy metal or the like. In this regard, the causative disease and pathology of skin irritation can be prevented or treated using the compositions and methods.

The term 'individual' in the present invention means all animals, including humans, who need to alleviate skin irritation or protect the skin, and includes diseased or sensitive skin carriers of diseases accompanied by skin irritation. By administering the composition of the present invention to an individual, skin irritation can be alleviated or suppressed, and the skin can be protected.

When the composition for alleviating skin irritation and protecting the skin of the present invention is a food composition, it can be used for skin irritation alleviation and skin protection derived from environmental pollution factors.

The food composition of the present invention includes all forms of functional foods, nutritional supplements, health foods, food additives, and feeds, and includes animals including humans or livestock. Subject to eating. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, the mace lignan or nutmeg extract of the present invention or a salt thereof may be prepared in the form of tea, juice, and drink for drinking or granulated, encapsulated, and powdered. In addition, it may be prepared in the form of a composition by mixing together with the mays lignan or nutmeg extract of the present invention and a known substance or active ingredient known to have an improvement effect on skin irritation.

Food compositions of this type can be prepared in various forms according to conventional methods known in the art. Drinks (including alcoholic beverages), fruits and processed foods (e.g. canned fruits, canned foods, jams, marmalades, etc.), fish, meat and processed foods (e.g. ham, sausages) Corn beef, etc.), breads and noodles (e.g. udon, buckwheat noodles, ramen, spagate, macaroni, etc.), juice, various drinks, cookies, syrup, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine , Plant protein, retort food, frozen food, various seasonings (eg miso, soy sauce, sauce, etc.) can be prepared by adding nutmeg extract or mace lignan.

In addition, as a nutritional supplement, but not limited to, it can be prepared by adding nutmeg extract or mace lignan to capsules, tablets, pills, and the like. In addition, the health functional food is not limited to this, for example, nutmeg extract or mace lignan itself is prepared in the form of tea, juice and drink to be liquefied, granulated, encapsulated and powdered for drinking (health drink). Can be consumed. In addition, in order to use nutmeg extract or mace lignan in the form of food additives, it can be prepared and used in powder or concentrate form. In addition, it can be prepared in the form of a composition by mixing with nutmeg extract or known active ingredients known to have a skin irritation and skin protection effect with mace lignan.

When the composition for relieving skin irritation and protecting the skin of the present invention is used as a health drink composition, the health drink composition may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, as in a conventional beverage. The natural carbohydrates described above include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g per 100 mL of the composition of the present invention, preferably about 0.02 to 0.03 g.

Nutmeg extract or mace lignan may be contained as an active ingredient in a food composition for skin irritation relief and skin protection, the amount of which is not particularly limited to an amount effective to achieve skin irritation relief and skin protection, but is not limited to the total weight of the total composition. It may be 0.01 to 100% by weight, preferably 0.01 to 50% by weight. The food composition of the present invention can be prepared by mixing with nutmeg extract or macy lignan together with other active ingredients known to be effective in skin irritation and skin protection.

In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acids, salts of pectic acids, alginic acids, salts of alginic acids, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, Glycerin, alcohol or carbonic acid. In addition, the health food of the present invention may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients may be used independently or in combination. The proportion of these additives is not critical, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

In addition, the composition for alleviating skin irritation and protecting the skin of the present invention may be a cosmetic composition. The cosmetic composition of the present invention can be easily prepared according to methods known in the art, including one or more excipients and additives commonly used in the field of manufacturing cosmetic compositions with the mace lignan or nutmeg extract of the present invention or salts thereof. You can.

The cosmetic composition of the present invention contains a nutmeg extract or mace lignan as an active ingredient and a basic cosmetic composition (face wash, cream, essence, cleansing foam and cleansing water-like cleansers, packs, and vodioyl), along with dermatologically acceptable excipients, It can be prepared in the form of color cosmetic composition (foundation, lipstick, mascara, makeup base), hair product composition (shampoo, conditioner, hair conditioner, hair gel) and soap. The excipients include, but are not limited to, for example, skin emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners and solvents. In addition, it may further include fragrances, pigments, fungicides, antioxidants, preservatives and moisturizers, and may include thickeners, inorganic salts, synthetic polymer materials, etc. for the purpose of improving physical properties.

The excipients include, but are not limited to, for example, skin emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners and solvents. In addition, it may further include fragrances, pigments, fungicides, antioxidants, preservatives and moisturizers, and may include thickeners, inorganic salts, synthetic polymer materials, etc. for the purpose of improving physical properties. For example, in the case of preparing a cleanser and soap with the cosmetic composition of the present invention, it can be easily prepared by adding a nutmeg extract or mace lignan to a conventional cleanser and soap base. In the case of manufacturing the cream, it can be prepared by adding a nutmeg extract or mace lignan or a salt thereof to a cream base of a general oil-in-water type (O / W). Synthetic or natural materials such as proteins, minerals, vitamins, etc. for the purpose of improving physical properties may be additionally added to fragrances, chelating agents, pigments, antioxidants, preservatives, and the like.

For example, in the case of preparing the face wash and soap containing the mace lignan or nutmeg extract of the present invention, it can be easily prepared by adding the mace lignan or nutmeg extract to the conventional face wash and soap base. In the case of manufacturing the cream, it may be prepared by adding mace lignan or nutmeg extract to a cream base of a general oil-in-water type (O / W). Synthetic or natural materials such as proteins, minerals, vitamins, etc. for the purpose of improving physical properties may be additionally added to fragrances, chelating agents, pigments, antioxidants, preservatives, and the like.

The content of nutmeg extract or mayslignan contained in the cosmetic composition of the present invention is not limited thereto, but is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight relative to the total weight of the total composition. If the content is less than 0.001% by weight, the desired anti-aging or anti-wrinkle effect cannot be expected, and when it is more than 10% by weight, there may be difficulties in safety or preparation of the formulation.

In addition, the present invention provides a composition for preventing skin contamination derived from environmental pollutants containing nutmeg extract or mace lignan as an active ingredient.

The composition may be provided in the form of a pharmaceutical composition, cosmetic composition, and food composition. Description of this is as described above.

The present invention provides a use of mace lignan or a nutmeg extract containing the same for preparing a preparation for skin irritation relief and skin protection derived from environmental pollution factors.

In addition, the present invention provides a method for alleviating skin irritation and protecting skin induced from environmental pollutants, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. do.

The present invention provides the use of mace lignan or nutmeg extract containing the same for preparing a formulation for preventing skin contamination derived from environmental pollution factors.

The present invention provides a method for preventing skin contamination derived from environmental pollutants, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof.

The 'effective amount' of the present invention, when administered to an individual, improves, treats, prevents, detects, diagnoses skin irritation and skin damage or skin contamination, or suppresses or reduces skin irritation and skin damage or skin contamination. In other words, the 'individual' may be an animal, preferably a mammal, particularly an animal including a human, or may be cells, tissues, organs, etc. derived from an animal. The subject may be a patient in need of the effect.

The 'treatment' of the present invention broadly refers to improving the symptoms of skin irritation and skin damage or skin contamination or skin irritation and skin damage or skin contamination, which heals, substantially prevents, or prevents these diseases May include, but is not limited to, alleviating, healing or preventing one symptom or most symptoms resulting from skin irritation and skin damage or skin contamination.

The term 'comprising' of the present invention is used in the same way as 'containing' or 'as a feature', and does not exclude additional component elements or method steps not mentioned in the composition or method. . The term 'consisting of' means excluding additional elements, steps or ingredients, which are not described separately. The term 'essentially consisting of' means that in the scope of a composition or method, it includes the described component elements or steps, as well as component elements or steps that do not materially affect its basic properties.

Nutmeg extract or mace lignan according to the present invention reduces the amount of expression of genes such as CYP1A1 mediated by XRE in skin cells, and thus has excellent skin irritation and skin protection functions derived from environmental pollutants, and is a food and cosmetic composition. Can be used for

Figure 1 shows the results of the inhibitory activity of luciferase increase mediated by XRE according to BaP treatment of nutmeg extract.

Figure 2 shows the results of the inhibitory activity of CYP1A1 expression increase according to BaP treatment of nutmeg extract.

Figure 3 shows the results of the inhibitory activity of increased luciferase mediated by XRE according to BaP treatment of mace lignan.

Figure 4 shows the results of the inhibitory activity of increased expression of CYP1A1 according to BaP treatment of mace lignan.

Figure 5 shows the results of the inhibitory activity of increased luciferase mediated by XRE by f treatment of macylignan.

6 shows the results of the inhibitory activity of increased expression of AhR mRNA by PM treatment of mays lignan.

Figure 7 shows the results of the inhibitory activity of increased expression of CYP1A1, CYP1B1, CYP1A2 mRNA by PM treatment of mays lignan.

Figure 8 shows the results of the effect of improving skin epidermal layer damage by PM treatment of mace lignan.

Hereinafter, the present invention will be described in detail.

However, the following examples are only to illustrate the present invention, the content of the present invention is not limited to the following examples.

실시예 1: 육두구 추출물의 제조Example 1: Preparation of nutmeg extract

1-1. 메탄올 추출물1-1. Methanol extract

After pulverizing the dried nutmeg with a mixer, 100 g of the ground nutmeg was added to 1 L of 100% methanol and extracted at room temperature for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component to obtain a nutmeg methanol extract.

1-2. 에탄올 추출물1-2. Ethanol extract

A nutmeg ethanol extract was obtained in the same manner as in Example 1-1, except that it was extracted at 50 ° C using 100% ethanol, 70% ethanol, 50% ethanol, and 30% ethanol.

1-3. 에틸아세테이트 추출물1-3. Ethyl acetate extract

A nutmeg ethyl acetate extract was obtained in the same manner as in Example 1-1, except that 100% ethyl acetate was used.

1-4. 헥산 추출물1-4. Hexane extract

A nutmeg hexane extract was obtained in the same manner as in Example 1-1, except that 100% hexane was used.

1-5. 열수 추출물1-5. Hot water extract

A nutmeg hot water extract was obtained in the same manner as in Example 1-2, except that water was used and the condition was 80 ° C.

1-6. 초고압 추출물1-6. Ultra high pressure extract

After grinding the dried nutmeg with a mixer, 76 mL of 18% ethanol was placed in a polyethylene pack, sealed, and then extracted using an ultra high pressure extraction device (Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan). The extraction conditions of the ultra-high pressure were 320 MPa and the extraction time was 5 min. Thereafter, the same method as in Example 1-1) was performed to obtain a nutmeg ultra-high pressure extract.

1-7. 초임계 추출물1-7. Supercritical extract

The dried nutmeg was ground with a mixer, and then 1 g of the ground nutmeg sample was charged into a sample cartridge and extracted using a supercritical device (SFX 3560, Isco Inc., Lincoln, NE, USA). The supercritical fluid extraction conditions were an extraction pressure of 40 MPa, an extraction temperature of 50, a supercritical carbon dioxide flow rate of 60 mL / min, and an extraction time of 60 min. When the supercritical extraction was completed, the pressure of the extraction device was lowered to release the supercritical fluid state, thereby obtaining a nutmeg supercritical extract.

1-8. 아임계 추출물1-8. Subcritical extract

50 g of crushed nutmeg was placed in a subcritical water reactor of a subcritical extraction device (Biovan, Gyeonggi, Korea) together with 1 L water and sealed. After sealing, the temperature of the reactor was increased to 200 ° C and the pressure was increased to 20 MPa, and when the temperature of the reactor reached 200 ° C, the temperature was maintained for 20 minutes to extract. After 20 minutes, the extract was transferred to a storage tank to which cooling water is supplied, rapidly cooled to 30 ° C, and centrifuged at 3,600 rpm for 30 minutes to separate the floating residue, and only the supernatant was taken. A subcritical extract of nutmeg was prepared by removing all water using a freeze dryer (ilShin Lab Co. Ltd., Seoul, Korea).

실시예Example 2: 2: 메이스리그난의Mace League 분리 및 구조결정 Separation and structure determination

In Example 1-2, the concentrated nutmeg ethanol extract obtained using 100% ethanol was partitioned into ethyl acetate, butanol, and water. The ethyl acetate fraction (4.2 g) was eluted with a solvent mixed with hexane and ethyl acetate at a ratio of 10: 1 (v / v) using silica gel column chromatography to obtain fraction III (1 g). Fraction III was subjected to column chromatography with a solvent mixed with hexane and ethyl acetate at a ratio of 20: 1 (v / v) to obtain fraction III-B (0.52 g). Then, fraction III-B was eluted with 80% methanol using Rp-18 column chromatography (Lichroprep RP-18 25-40 um; Merck & Co.) to obtain single substance fraction III-B-2 (0.5 g). Got.

¹ H-NMR spectrum and ¹³ C-NMR spectrum were measured at 600 MHz and 150 MHz (solvent: DMSO), respectively, in order to determine the structure of the isolated single substance III-B-2. ¹³ C-NMR spectrum and the ^{^{^{1 H-NMR 1 H- 1 H}}} COSY spectrum and ¹ H- ¹³ to measure the correlation of the correlation of the ^¹ H- ¹ H, based on the result of the spectrum related to the ¹ H- ¹³ C HMBC C Spectra were measured. As a result of measurement by EI / MS for mass spectrometry of the isolated single substance, [M] + was observed at m / z 328 in EI / MS and the molecular weight was found to be 328, and the molecular formula was C ₂₀ H ₂₄ It was O ₄ . In addition, after dissolving 20 mg of the separated single substance Ⅲ-B-2 in 2 ml of chloroform (CHCl ₃ ), the non-linearity ([α] D) value was measured with a Polarimeter (Automatic Polarimeter, APIII-589, Rodulph, NJ, USA). As a result, [α] D = +4.0 (CHCl ₃ _, c = 1.0). Results for the above ¹ H-NMR, ¹³ C-NMR, ¹ H- ¹ H COSY, ¹ H- ¹³ C HMBC, EI / MS and [α] D and previously published research reports (Woo, WS et al. , Phytochemistry, 26: 1542-1543, 1987). As a result, it was confirmed that the isolated single substance was macelignan represented by Chemical Formula 1.

[Formula 1]

실시예 3: 육두구 추출물의 BaP 처리에 따른 XRE에 의해 매개되는 luciferase 증가 억제 활성Example 3: XP-mediated luciferase increase inhibitory activity according to BaP treatment of nutmeg extract

COS-7 monkey kidney cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's media (DMEM; Hyclone) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) 24- Incubated in well plates for 24 hours or more. For transfection, serum-free DMEM (Hyclone) was mixed with plus reagent (Aptabio, Gyeonggi, Korea) and XRE plasmid and incubated for 15 minutes. Then, the lipofecter reagent (Aptabio) was mixed and incubated for 15 minutes at room temperature, and then treated with cells. After 4 hours, cells were stabilized in DMEM (Hyclone) containing 10% FBS (Hyclone) for 24 hours. After stabilization, the nutmeg 100% ethanol extract prepared in Example 1-2) with 5 μM of benzo (a) pyrene (BaP; Sigma-aldrich, St. Louis, MO, USA) belonging to a polycyclic aromatic hydrocarbon was added to 0.5 and Treatment was at 1 μg / mL. After 24 hours, cells were lysed with NP-40 lysis buffer (Elpis, Daejeon, Korea) containing proteinase inhibitor cocktail (Sigma-aldrich). Luciferase activity was measured using a luciferase substrate (Promega, Madison, WI, USA) and then using a Microlumateplus LB 96V luminometer (Berthlod, Wildbab, Germany).

As a result, as shown in Figure 1, BaP significantly increased the activity of luciferase under XRE control ( ^## p <0.01), and increased luciferase activity was significantly ( ^** p <0.01). This means that the nutmeg extract of the present invention effectively reduces skin irritation caused by environmental pollution factors.

실시예 4: 육두구 추출물의 BaP 처리에 따른 CYP1A1 발현량 증가 저해 활성Example 4: Inhibitory activity of CYP1A1 expression increase according to BaP treatment of nutmeg extract

The skin keratinocytes HaCaT (ATCC) was placed in a 6-well plate with DMEM (Hyclone) containing 10% FBS (Hyclone) to 2 x 10 ⁵ cells / mL. When the cell density was about 80-85%, the nutmeg 100% ethanol extract of Example 1-2 was treated with 0.5 and 1 μg / mL for 24 hours with 5 μM BaP (Sigma-aldrich). After incubation, total RNA was isolated using a TRIzol reagent (Takara, Tokyo, Japan). Total RNA isolated was quantified using a nanodrop (NanoDrop 1000; Thermo Fisher Scientific Inc., MA, USA). Quantitative 16 μL RNA was synthesized by cDNA under conditions of 42 ° C 55 minutes and 70 ° C 15 minutes using Reverse Transcriptase Premix (Elpis) and PCR machine (Gene Amp PCR System 2700; Applied Biosystems, MA, USA). Of 16 cLNA generated cDNA, 3 μL cDNA, the following specific primers (Bioneer, Daejeon, Korea) and PCR premix (Elpis) at 95 ° C for 30 seconds, 60 ° C for 1 minute, and 72 ° C for 1 minute 30 times PCR was performed repeatedly. The cDNA amplified by PCR was separated by electrophoresis with a 1.5% agarose gel, and the cDNA band was confirmed using a G; BOX EF imaging system (Syngene). The results are shown in FIG. 2.

CYP1A1

Forward primer: 5'-CTACCCAACCCTTCCCTGAAT-3 '(SEQ ID NO: 1)

Reverse primer: 5'-CGCCCCTTGGGGATGTAAAA-3 '(SEQ ID NO: 2)

GAPDH

Forward primer: 5'-ATTGTTGCCATCAATGACCC-3 '(SEQ ID NO: 3)

Reverse primer: 5'-TCGCCCCACTTGATTTTGGA-3 '(SEQ ID NO: 4)

As a result, as shown in FIG. 2, when the BaP treatment was performed, the expression level of CYP1A1 mRNA mediated by XRE increased, but it decreased in a concentration-dependent manner as the nutmeg extract was treated. This means that the nutmeg extract of the present invention effectively reduces skin irritation caused by environmental pollution factors.

실시예 5: 육두구 추출물의 PM 처리에 따른 XRE에 의해 매개되는 luciferase 증가 억제 활성Example 5: XRE-mediated luciferase increase inhibitory activity according to PM treatment of nutmeg extract

Nutmeg extract 50% ethanol extract and 100% ethanol extract prepared in Example 1-2, nutmeg ethyl acetate prepared in Example 1-3 to examine the luciferase inhibitory activity mediated by XRE induced by PM of nutmeg extract Extract, nutmeg hexane extract prepared in Example 1-4, Nutmeg hot water extract prepared in Example 1-5 was treated with cells at 1 μg / mL, and inducers were standardized fine dust (PM; NIST, Gaithersburg instead of BaP). , MD, USA) The experiment was carried out in the same manner as in Example 3, except that 100 μg / mL was used.

As a result, as shown in Table 1 below, PM significantly increased the activity of luciferase under XRE control ( ^## p <0.01), and the increased luciferase activity was significantly ( ^** p <0.01). This means that the nutmeg extract of the present invention effectively reduces skin irritation caused by environmental pollution factors.

군group	상대적 luciferase 활성(%)Relative luciferase activity (%)
대조군Control	100.0 ± 4.84100.0 ± 4.84
PM 처리군PM treatment group	271.38 ± 5.99 ^## 271.38 ± 5.99 ^##
PM + 육두구 50% 에탄올 추출물 처리군PM + Nutmeg 50% ethanol extract treatment group	207.24 ± 2.62 ^ 207.24 ± 2.62 ^
PM + 육두구 100% 에탄올 추출물 처리군PM + Nutmeg 100% ethanol extract treatment group	186.94 ± 3.21 ^ 186.94 ± 3.21 ^
PM + 육두구 에틸아세테이트 추출물 처리군PM + Nutmeg ethyl acetate extract treatment group	190.73 ± 9.92 ^ 190.73 ± 9.92 ^
PM + 육두구 헥산 추출물 처리군PM + Nutmeg hexane extract treatment group	201.79 ± 4.71 ^ 201.79 ± 4.71 ^
PM + 육두구 열수 추출물 처리군PM + Nutmeg hot water extract treatment group	182.89 ± 3.52 ^ 182.89 ± 3.52 ^

실시예 6: 메이스리그난의 BaP 처리에 따른 CYP1A1 발현량 증가 저해 활성Example 6: Inhibitory activity of CYP1A1 expression increase according to BaP treatment of maylignan

In order to investigate the inhibitory activity of CYP1A1 mRNA expression level of mays lignan, the cells were treated with 1 and 5 μM of mays lignan prepared in Example 2-1 to conduct experiments in the same manner as in Example 4.

As a result, as shown in FIG. 4, when the BaP treatment was performed, the expression level of CYP1A1 mRNA mediated by XRE increased, but it was decreased in a concentration-dependent manner with the treatment of macylignan. This means that the mac lignan of the present invention effectively reduces skin irritation caused by environmental pollution factors.

실시예 7: 메이스리그난의 PM처리에 의한 XRE에 의해 매개되는 luciferase 증가 억제 활성Example 7: Inhibitory activity of increased luciferase mediated by XRE by PM treatment of mays lignan

To examine the luciferase inhibitory activity mediated by XRE induced by PM of mays lignan, the mace lignan prepared in Example 2-1) was treated with cells at 0.5 and 1 μM to induce the inducer PM 100 μg / mL. The experiment was conducted in the same manner as in Example 3, except that it was used.

As a result, as shown in FIG. 5, PM increased the activity of luciferase under XRE control significantly ( ^## p <0.01), and the increased luciferase activity was significantly ( ^** p <0.01). This means that the mac lignan of the present invention effectively reduces skin irritation caused by environmental pollution factors.

실시예 8: 메이스리그난의 PM처리에 의한 AhR mRNA 발현량 증가 저해 활성Example 8: Inhibitory activity of increased expression of AhR mRNA by PM treatment of mace lignan

In order to investigate the inhibitory activity of the mRNA expression level of AhR induced by PM of mays lignan, the cells were treated with 0.5 and 1 μM of mays lignan prepared in Example 2-1 to use 100 μg / mL of PM. The experiment was conducted in the same manner as in Example 4, except that the point and the AhR primer were used.

AhR

Forward primer: 5'-CCACTTCAGCCACCATCCAT-3 '(SEQ ID NO: 5)

Reverse primer: 5'-AAGCAGGCGTGCATTAGACT-3 '(SEQ ID NO: 6)

As a result, as shown in FIG. 6, when the PM was treated, the mRNA expression level of AhR was increased, but it was decreased in a concentration-dependent manner with the treatment of macylignan. This means that the mays lignan of the present invention effectively reduces skin irritation caused by environmental pollutants by reducing the mRNA expression level of receptors to which environmental pollutants can bind.

실시예 9: 메이스리그난의 PM처리에 의한 CYP1A1, CYP1B1, CYP1A2 mRNA 발현량 증가 저해 활성Example 9: Inhibitory activity of increased expression of CYP1A1, CYP1B1, CYP1A2 mRNA by PM treatment of mace lignan

To investigate the activity of CYP1A1, CYP1B1, and CYP1A2 mRNA expression induced by PM of mays lignan, the mace lignan prepared in Example 2-1 was treated with cells at 0.5 and 1 μM to induce the inducer PM 100 μg / mL Experiments were conducted in the same manner as in Example 4, except that and CYP1B1 and CYP1A2 primers were additionally used.

CYP1B1

Forward primer: 5'-CTGCGACTCCAGTTGTGAGA-3 '(SEQ ID NO: 7)

Reverse primer: 5'-AAGGAACTGGGACCTTTGCC-3 '(SEQ ID NO: 8)

CYP1A2

Forward primer: 5'-GCACTGTCAAGGATGAGCCA-3 '(SEQ ID NO: 9)

Reverse primer: 5'-TGAGTGTTCTTCACGAGGCTG-3 '(SEQ ID NO: 10)

As a result, as shown in FIG. 7, when the PM was treated, the mRNA expression levels of CYP1A1, CYP1B1, and CYP1A2 activated by AhR and mediated by XRE were increased, but the concentration was decreased depending on the treatment of macylignan. This means that the mac lignan of the present invention effectively reduces skin irritation caused by environmental pollution factors.

실시예 10: 메이스리그난의 PM처리에 의한 피부 표피층 손상 개선 효과Example 10: Effect of improving skin epidermal layer damage by PM treatment of mace lignan

In order to investigate the activity of inhibiting skin epidermal layer damage induced by PM of Maylignan, a 3D artificial skin model (Neoderm-ED, Tego Science) was purchased and tested. The experimental group was divided into normal group, PM 100 μg / mL treatment group, mace lignan 0.5 μM treatment group, and mace lignan 1 μM treatment group, and 6 artificial skin tissues were used for each group. Neoderm-ED was prepared according to the method of manufacturing the tegoscience, and the experiment was conducted after stabilizing artificial skin tissue at 5% CO ₂ and 37 ° C. conditions using a dedicated medium provided by tegoscience for 6 hours. Skin damage caused by PM was induced by treating PM 100 μg / mL with 50 μL per well on the Neoderm-ED surface, and DPBS was treated with the same dose in the normal group. Simultaneously with PM induction, the mace lignan prepared in Example 2-1 was treated with Neoderm-ED's exclusive medium at 0.5 and 1 μM to induce improvement of skin damage due to PM. The cells were cultured for 72 hours at 5% CO ₂ and 37 ° C., and PM and mace lignan were further treated every 24 hours. After the 72-hour incubation, the artificial skin tissue was fixed with 10% formalin to produce a paraffin block. Hematoxylin & eosin staining was performed to measure the improvement of skin damage caused by PM of mace lignan from the histological aspect using the fixed tissue, and the stained tissue was eXcope T500 camera (DIXI Science, Daejeon) , Korea) was observed with a photochemical microscope (CK40; Olympus, Tokyo, Japan).

As a result, as shown in FIG. 8, structural morphological changes of the stratum corneum of the epidermal layer of the skin were observed in the PM-treated group compared to the normal group, and the total thickness of the granular layer, the polar layer, and the base layer belonging to the epidermal layer compared to the normal group. It was confirmed that it was very reduced. On the contrary, it was confirmed that when the macylignan was treated, the morphology of the stratum corneum and the total thickness of the epidermal layer excluding the stratum corneum were recovered in a concentration-dependent manner similar to the normal group. This means that the machlignan of the present invention has an effect of inhibiting and improving damage to the skin epidermal layer due to PM.

Hereinafter, an example of preparing skin stimulation and skin protection or a pharmaceutical, food, or cosmetic product containing nutmeg extract or mace lignan as an active ingredient according to the present invention will be described, but the present invention is not intended to be limited thereto, but only specifically It is. Medicines, foods and cosmetics of Preparation Examples 1 to 3 were prepared according to the following compositional components and composition ratios with nutmeg extract or mace lignan having excellent skin irritation alleviation and skin protection activity.

제조예 1: 의약품Preparation Example 1: Pharmaceutical

1) Powder

After mixing the nutmeg extract of Example 1 to 2 or 50 mg of mace lignan and 2 g of crystalline cellulose, a powder was prepared by filling in an airtight bag according to a conventional powder manufacturing method.

2) Tablet

After mixing the nutmeg extract of Example 1 to 2, or 50 mg of maylignan, 400 mg of crystalline cellulose, and 5 mg of magnesium stearate, tablets were prepared by tableting according to a conventional tablet manufacturing method.

3) Capsule

After mixing the nutmeg extract of Example 1 to 2, or 30 mg of maylignan, whey protein, 100 mg of crystalline cellulose, 400 mg of magnesium stearate, and filling it into a gelatin capsule according to a conventional capsule preparation method, a capsule is prepared. Did.

제조예 2: 식품Preparation Example 2: Food

1) Manufacture of health food

Nutmeg extract or mays lignan 1000 mg, vitamin A acetate 70 μL, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 μg, vitamin C 10 mg of Examples 1 to 2 , 10 μg biotin, 1.7 mg nicotinamide, 50 μg folic acid, 0.5 mg calcium pantothenate, 1.75 mg ferrous sulfate, 0.82 mg zinc oxide, 25.3 mg magnesium carbonate, 15 mg potassium phosphate, 55 mg calcium diphosphate, Potassium citrate 90 mg, calcium carbonate 100 mg, and magnesium chloride 24.8 mg can be prepared by mixing, and the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method, and then granulated It can be prepared and used in the preparation of a health food composition according to a conventional method.

2) Production of health drinks

Nutmeg extract of Examples 1 to 2 or 1000 mg of maylignan, 1000 mg of citric acid, 100 g of oligosaccharides, 2 g of plum concentrate, and 1 g of taurine were added to purified water to add the above ingredients according to the general method for preparing a health drink of 900 mL. After mixing, after stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered, obtained in a sterilized 2 L container, sealed and sterilized, then refrigerated and then used in the manufacture of a health drink composition.

3) Chewing gum

Chewing gum was prepared by a conventional method by mixing 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of fragrance, and 2% by weight of water and 0.1% by weight of nutmeg extract or mace lignan of Examples 1 to 2 above.

4) Candy

Candy was prepared by a conventional method by mixing 60% by weight of sugar, 39.8% by weight of starch syrup and 0.1% by weight of fragrance and 0.1% by weight of nutmeg extract or maceignan of Examples 1 to 2 above.

5) Biscuit

Power 1st class 25.59% by weight, Gravity 1st class 22.22% by weight, 4.80% by weight per white sugar, 0.73% by weight salt, 0.78% by weight of glucose, 11.78% by weight of palm shortening, 1.54% by weight of ammonium, 0.17% by weight of sodium bicarbonate, 0.16% by weight of sodium bisulfite , Rice flour 1.45% by weight, vitamin B 0.0001% by weight, milk flavor 0.04% by weight, water 20.6998% by weight, whole milk powder 1.16% by weight, substitute milk powder 0.29% by weight, calcium phosphate 0.03% by weight, spray salt 0.29% by weight and spray Biscuits were prepared by a conventional method by mixing 7.27% by weight with 1% by weight of the nutmeg extract or mace lignan of Examples 1 to 2 above.

제조예Manufacturing example 3: 화장품 3: Cosmetics

1) Nutrition lotion (milk lotion)

Nutmeg extract or mace lignan of Examples 1 to 2 was prepared in the nutritional lotion according to a conventional method with the ingredients and contents of Table 2 below.

배합성분 Ingredients	제조예1-1(중량%)Preparation Example 1-1 (% by weight)
육두구 추출물 또는 메이스리그난Nutmeg extract or mace lignan	2.02.0
스쿠알란Squalane	5.05.0
밀납Wax	4.04.0
폴리솔베이트 60Polysorbate 60	1.51.5
솔비탄세스퀴올레이트Sorbitan sesquioleate	1.51.5
유동파라핀Floating paraffin	0.50.5
카프릴릭/카프릭트리글리세라이드Caprylic / Capric Triglyceride	5.05.0
글리세린glycerin	3.03.0
부틸렌글리콜Butylene glycol	3.03.0
프로필렌글리콜Propylene glycol	3.03.0
카르복시비닐폴리머Carboxyvinyl polymer	0.10.1
트리에탄올아민Triethanolamine	0.20.2
방부제, 색소, 향료Preservatives, pigments, flavors	적량Proper
정제수Purified water	to 100to 100

2) Flexible lotion (skin lotion)

The nutmeg extract or mays lignan of Examples 1 to 2 was prepared with a flexible lotion according to a conventional method with the ingredients and contents of Table 3 below.

배합성분 Ingredients	제조예1-2(중량%)Preparation Example 1-2 (% by weight)
육두구 추출물 또는 메이스리그난Nutmeg extract or mace lignan	2.02.0
글리세린glycerin	3.03.0
부틸렌글리콜Butylene glycol	2.02.0
프로필렌글리콜Propylene glycol	2.02.0
카르복시비닐폴리머Carboxyvinyl polymer	0.10.1
PEG 12 노닐페닐에테르PEG 12 nonylphenyl ether	0.20.2
폴리솔베이트 80Polysorbate 80	0.40.4
에탄올ethanol	10.010.0
트리에탄올아민Triethanolamine	0.10.1
방부제, 색소, 향료Preservatives, pigments, flavors	적량Proper
정제수Purified water	to 100to 100

3) Nutrition cream

Nutmeg extract or mays lignan of Examples 1 to 2 was prepared in the nutritional cream according to a conventional method with the components and contents of Table 4 below.

배합성분 Ingredients	제조예1-3(중량%)Preparation Example 1-3 (% by weight)
육두구 추출물 또는 메이스리그난Nutmeg extract or mace lignan	2.02.0
폴리솔베이트 60Polysorbate 60	1.51.5
솔비탄세스퀴올레이트Sorbitan sesquioleate	0.50.5
PEG60 경화피마자유PEG60 hard castor oil	2.02.0
유동파라핀Floating paraffin	1010
스쿠알란Squalane	5.05.0
카프릴릭/카프릭트리글리세라이드Caprylic / Capric Triglyceride	5.05.0
글리세린glycerin	5.05.0
부틸렌글리콜Butylene glycol	3.03.0
프로필렌글리콜Propylene glycol	3.03.0
트리에탄올아민Triethanolamine	0.20.2
방부제antiseptic	적량Proper
색소Coloring	적량Proper
향료Spices	적량Proper
정제수Purified water	to 100to 100

4) Massage cream

Massage cream was prepared according to a conventional method with the ingredients and contents of the nutmeg extract or mace lignan of Examples 1 to 2 below.

배합성분 Ingredients	제조예1-4(중량%)Preparation Example 1-4 (% by weight)
육두구 추출물 또는 메이스리그난Nutmeg extract or mace lignan	1.01.0
밀납Wax	10.010.0
폴리솔베이트 60Polysorbate 60	1.51.5
PEG 60 경화피마자유 PEG 60 hardened castor oil	2.02.0
솔비탄세스퀴올레이트Sorbitan sesquioleate	0.80.8
유동파라핀Floating paraffin	40.040.0
스쿠알란Squalane	5.05.0
카프릴릭/카프릭트리글리세라이드Caprylic / Capric Triglyceride	4.04.0
글리세린glycerin	5.05.0
부틸렌글리콜Butylene glycol	3.03.0
프로필렌글리콜Propylene glycol	3.03.0
트리에탄올아민Triethanolamine	0.20.2
방부제, 색소, 향료Preservatives, pigments, flavors	적량Proper
정제수Purified water	to 100to 100

5) Pack

The nutmeg extract or mace lignan of Examples 1 to 2 was prepared according to a conventional method with the ingredients and contents of Table 6 below.

배합성분 Ingredients	제조예1-5(중량%)Preparation Example 1-5 (% by weight)
육두구 추출물 또는 메이스리그난Nutmeg extract or mace lignan	1.01.0
폴리비닐알콜Polyvinyl alcohol	13.013.0
소듐카르복시메틸셀룰로오스Sodium carboxymethylcellulose	0.20.2
글리세린glycerin	5.05.0
알란토인Allantoin	0.10.1
에탄올ethanol	6.06.0
PEG 12 노닐페닐에테르PEG 12 nonylphenyl ether	0.30.3
폴리솔베이트 60Polysorbate 60	0.30.3
방부제, 색소, 향료Preservatives, pigments, flavors	적량Proper
정제수Purified water	to 100to 100

6) Gel

The nutmeg extract or mace lignan of Examples 1 to 2 was prepared according to a conventional method with the ingredients and contents of Table 7 below.

배합성분Ingredients	제조예1-6(중량%)Preparation Example 1-6 (wt%)
육두구 추출물 또는 메이스리그난Nutmeg extract or mace lignan	0.50.5
에틸렌디아민초산나트륨Sodium ethylenediamine acetate	0.050.05
글리세린glycerin	5.05.0
카르복시비닐폴리머Carboxyvinyl polymer	0.30.3
에탄올ethanol	5.05.0
PEG 60 경화피마자유 PEG 60 hardened castor oil	0.50.5
트리에탄올아민Triethanolamine	0.30.3
방부제, 색소, 향료Preservatives, pigments, flavors	적량Proper
정제수Purified water	to 100to 100

As described above, the present invention relates to a composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or macy lignan as an active ingredient. More specifically, the nutmeg extract and mays lignan of the present invention reduced the expression of CYP1A1 gene mediated by XRE in skin cells and improved the skin damaged by fine dust, and thus skin irritation caused by fine dust, heavy metals, or yellow dust It has an excellent effect on relief and skin protection. Therefore, the nutmeg extract and mace lignan of the present invention is a natural product, and thus can be safely used without side effects, and is highly industrially applicable because it can provide a composition showing excellent effects on skin irritation and skin protection.

Claims

A pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollutants containing Mayslignan represented by the following Chemical Formula 1 or nutmeg extract containing the same as an active ingredient.

[Formula 1]
[5] The pharmaceutical composition for relieving skin irritation and protecting skin derived from environmental pollutants according to claim 1, wherein the mace lignan represented by Chemical Formula 1 is isolated from nutmeg extract.
The method of claim 1, wherein the nutmeg extract is a pharmaceutical composition for skin irritation relief and skin protection derived from environmental pollutants, characterized in that the seeds of the nutmeg extract.
The method of claim 1, wherein the nutmeg extract is from an environmental pollution factor characterized in that the nutmeg is extracted with one or more solvents or ultra-high pressure selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, subcritical fluid and supercritical fluid. Pharmaceutical composition for alleviating induced skin irritation and protecting skin.
The method of claim 1, wherein the skin irritation is characterized in that it is selected from the group consisting of dermatitis, atopy, psoriasis, acne, eczema, and skin cancer. A pharmaceutical composition for skin irritation relief and skin protection derived from environmental pollution factors.
A food composition for relieving skin irritation and protecting skin derived from environmental contaminants containing mace lignan represented by Formula 1 or a nutmeg extract containing the same as an active ingredient.

[Formula 1]
Cosmetic composition for relieving skin irritation and protecting skin derived from environmental contaminants containing as an active ingredient mace lignan represented by Formula 1 or nutmeg extract containing the same.

[Formula 1]
A pharmaceutical composition for preventing skin contamination derived from an environmental pollution factor containing mayslignan represented by the following Chemical Formula 1 or nutmeg extract containing the same as an active ingredient.

[Formula 1]
A food composition for preventing skin contamination derived from an environmental pollution factor containing mace lignan represented by the following Chemical Formula 1 or a nutmeg extract containing the same as an active ingredient.

[Formula 1]
A cosmetic composition for preventing skin contamination derived from environmental pollution factors containing mayslignan represented by the following Chemical Formula 1 or nutmeg extract containing the same as an active ingredient.

[Formula 1]
Use of mace lignan represented by the following formula (1) or nutmeg extract containing the same to prepare an agent for alleviating skin irritation and protecting skin derived from environmental pollution factors.

[Formula 1]
A method for alleviating skin irritation and protecting skin derived from environmental pollutants, comprising administering an effective amount of a composition containing mayslignan represented by Formula 1 or nutmeg extract containing the same as an active ingredient to an individual in need thereof.

[Formula 1]
Use of mace lignan represented by the following Chemical Formula 1 or nutmeg extract containing the same for preparing a preparation for preventing skin contamination derived from environmental pollution factors.

[Formula 1]
A method for preventing skin contamination derived from environmental pollutants, comprising administering an effective amount of a composition containing mayslignan represented by the following Chemical Formula 1 or nutmeg extract containing it as an active ingredient to an individual in need thereof.

[Formula 1]